BioCentury
ARTICLE | Company News

Breakthrough designation for Roche's alectinib

September 24, 2013 12:53 AM UTC

Roche (SIX:ROG; OTCQX:RHHBY) said FDA granted breakthrough therapy designation for alectinib (RO5424802/ CH5424802) to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC...